Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies (Q38705659)

5 September 2017

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies (English)

1 reference

non-alcoholic steatohepatitis

5 September 2017

0 references

1 reference

Giovanni Musso

1

1 reference

PubMed ID

26794269

5 September 2017

Maurizio Cassader

series ordinal

2

1 reference

PubMed ID

26794269

5 September 2017

Roberto Gambino

series ordinal

3

1 reference

5 September 2017

22 January 2016

1 reference

Nature Reviews Drug Discovery

5 September 2017

1 reference

5 September 2017

15

1 reference

5 September 2017

4

1 reference

5 September 2017

249-274

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2015.3

5 September 2017

0 references

cites work

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Gut-liver axis, nutrition, and non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Peroxisome proliferator-activated receptor-gamma coactivator 1alpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Farnesoid X receptor is essential for normal glucose homeostasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

GW4064, a farnesoid X receptor agonist, upregulates adipokine expression in preadipocytes and HepG2 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fundamentals of FGF19 & FGF21 action in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Targeting xenobiotic receptors PXR and CAR in human diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Pregnane X receptor modulates the inflammatory response in primary cultures of hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The protective role of pregnane X receptor in lipopolysaccharide/D-galactosamine-induced acute liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Identification of three novel natural product compounds that activate PXR and CAR and inhibit inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Acetylation of pregnane X receptor protein determines selective function independent of ligand activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor α to regulate metabolic hormone FGF21.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Peroxisome proliferator-activated receptor α positively regulates complement C3 expression but inhibits tumor necrosis factor α-mediated activation of C3 gene in mammalian hepatic-derived cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Discontinued in 2013: diabetic drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Saroglitazar for the treatment of dyslipidemia in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

A lipidomic analysis of nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Regulation of lipid homeostasis by the bifunctional SREBF2-miR33a locus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Curcumin inhibits srebp-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol and EGCG bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hepatic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Chronic supplementation of proanthocyanidins reduces postprandial lipemia and liver miR-33a and miR-122 levels in a dose-dependent manner in healthy rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Ceramide: a simple sphingolipid with unique biophysical properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Mir-33 regulates cell proliferation and cell cycle progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

MicroRNA-33a inhibits lung cancer cell proliferation and invasion by regulating the expression of β-catenin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Induction of ER stress-mediated apoptosis by ceramide via disruption of ER Ca(2+) homeostasis in human adenoid cystic carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Activation of sphingosine kinase 2 by endoplasmic reticulum stress ameliorates hepatic steatosis and insulin resistance in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Autophagy in the light of sphingolipid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

A new mechanism of lipotoxicity: Calcium channel blockers as a treatment for nonalcoholic steatohepatitis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Functional inhibitors of acid sphingomyelinase (FIASMAs).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Metabolomic profiling in liver of adiponectin-knockout mice uncovers lysophospholipid metabolism as an important target of adiponectin action.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

DGAT enzymes are required for triacylglycerol synthesis and lipid droplets in adipocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Roles of Acyl-CoA:Diacylglycerol Acyltransferases 1 and 2 in Triacylglycerol Synthesis and Secretion in Primary Hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Carbon tetrachloride-induced hepatic injury through formation of oxidized diacylglycerol and activation of the PKC/NF-κB pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Roles of Oxidized Diacylglycerol for Carbon Tetrachloride-induced Liver Injury and Fibrosis in Mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

PKCδ as a regulator for TGFβ1-induced α-SMA production in a murine nonalcoholic steatohepatitis model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A:diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: a link to amelioration of fatty liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Discovery of indolyl acrylamide derivatives as human diacylglycerol acyltransferase-2 selective inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Discovery of a novel class of diacylglycerol acyltransferase 2 inhibitors with a 1H-pyrrolo[2,3-b]pyridine core

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Trafficking of the transcription factor Nrf2 to promyelocytic leukemia-nuclear bodies: implications for degradation of NRF2 in the nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The emerging role of redox-sensitive Nrf2-Keap1 pathway in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Nrf2 deletion causes "benign" simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not w

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Myeloid deletion of nuclear factor erythroid 2-related factor 2 increases atherosclerosis and liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Sulforaphane attenuates hepatic fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Oltipraz upregulates the nuclear factor (erythroid-derived 2)-like 2 [corrected](NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The pharmacology of resveratrol in animals and humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The effects of 30 days resveratrol supplementation on adipose tissue morphology and gene expression patterns in obese men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Differential effects of low-dose resveratrol on adiposity and hepatic steatosis in diet-induced obese mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Dietary quercetin ameliorates nonalcoholic steatohepatitis induced by a high-fat diet in gerbils

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Endogenous and exogenous mediators of quercetin bioavailability.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fibroblast growth factor 21 improves insulin sensitivity and synergizes with insulin in human adipose stem cell-derived (hASC) adipocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Obesity is a fibroblast growth factor 21 (FGF21)-resistant state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Emerging molecular targets for the treatment of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

AMPK activation prevents excess nutrient-induced hepatic lipid accumulation by inhibiting mTORC1 signaling and endoplasmic reticulum stress response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: a mechanism including AMPKα1/SIRT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Curcumin regulates peroxisome proliferator-activated receptor-γ coactivator-1α expression by AMPK pathway in hepatic stellate cells in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

mTOR: a pharmacologic target for autophagy regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

AMPK phosphorylation of raptor mediates a metabolic checkpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

S6 kinase 2 deficiency enhances ketone body production and increases peroxisome proliferator-activated receptor alpha activity in the liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Inflammatory stress increases hepatic CD36 translational efficiency via activation of the mTOR signalling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Disruption of mammalian target of rapamycin complex 1 in macrophages decreases chemokine gene expression and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Role of S6K1 in regulation of SREBP1c expression in the liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Effects of the mTOR inhibitor rapamycin on monocyte-secreted chemokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

ALCAT1 controls mitochondrial etiology of fatty liver diseases, linking defective mitophagy to steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

mTORC1 controls fasting-induced ketogenesis and its modulation by ageing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Phosphorylation-independent mTORC1 inhibition by the autophagy inducer Rottlerin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

2-(3-Benzoylthioureido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ameliorates metabolic disorders in high-fat diet-fed mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Extracellular ATP induces P2X7 receptor activation in mouse Kupffer cells, leading to release of IL-1β, HMGB1, and PGE2, decreased MHC class I expression and necrotic cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Activation of N-methyl-d-aspartate receptor downregulates inflammasome activity and liver inflammation via a β-arrestin-2 pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic recruitment of the inflammatory Gr1+monocyte subset upon liver injury promotes hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Roles of chemokine ligand-2 (CXCL2) and neutrophils in influencing endothelial cell function and inflammation of human adipose tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Increased macrophage migration into adipose tissue in obese mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Monocyte chemoattractant protein deficiency fails to restrain macrophage infiltration into adipose tissue [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

C-C motif chemokine receptor 9 positive macrophages activate hepatic stellate cells and promote liver fibrosis in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

CXCR3 ligands in disease and therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Chemokine receptor CCR6-dependent accumulation of γδ T cells in injured liver restricts hepatic inflammation and fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The fractalkine receptor CX₃CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic inflammation and progressive liver fibrosis in chronic liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Cardioprotective potential of annexin-A1 mimetics in myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Annexin A1 modulates natural and glucocorticoid-induced resolution of inflammation by enhancing neutrophil apoptosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Annexin A1 mimetic peptide controls the inflammatory and fibrotic effects of silica particles in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Attenuation of plasma annexin A1 in human obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Increased adiposity in annexin A1-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resolvin D1 binds human phagocytes with evidence for proresolving receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resolvin D1 and resolvin D2 govern local inflammatory tone in obese fat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The human serum metabolome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 regulates hepatic progenitor cell expansion during liver injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resolvin D1 reduces ER stress-induced apoptosis and triglyceride accumulation through JNK pathway in HepG2 cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Resolvin D1 primes the resolution process initiated by calorie restriction in obesity-induced steatohepatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Proresolving actions of a new resolvin D1 analog mimetic qualifies as an immunoresolvent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3: an emerging all-out player in metabolic disorders and their complications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Expression of galectin-3 modulates T-cell growth and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Implication of galectin-3 in Wnt signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Gal-3 regulates the capacity of dendritic cells to promote NKT-cell-induced liver injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Therapy of experimental NASH and fibrosis with galectin inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

5-lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor alpha-induced hepatocyte damage in hyperlipidemia-prone ApoE-null mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Human lysyl oxidase-like 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatic stellate cells and portal fibroblasts are the major cellular sources of collagens and lysyl oxidases in normal liver and early after injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

An overview of hedgehog signaling in fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Vismodegib suppresses TRAIL-mediated liver injury in a mouse model of nonalcoholic steatohepatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Nanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Cellular senescence controls fibrosis in wound healing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.3

Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes

31 March 2020

1 reference

12 December 2020

Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway

1 reference

12 December 2020

Therapeutic targeting of liver inflammation and fibrosis by nanomedicine

1 reference

12 December 2020

Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

1 reference

12 December 2020

Information obtained by liver biopsy in 100 tuberculous patients

1 reference

12 December 2020

Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways

1 reference

12 December 2020

CCR1 and CCR5 promote hepatic fibrosis in mice

1 reference

12 December 2020

Targeting pro-resolution pathways to combat chronic inflammation in COPD

1 reference

12 December 2020

CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis

1 reference

12 December 2020

Pioglitazone, quercetin and hydroxy citric acid effect on cytochrome P450 2E1 (CYP2E1) enzyme levels in experimentally induced non alcoholic steatohepatitis (NASH).

1 reference

12 December 2020

Rapamycin improves palmitate-induced ER stress/NF κ B pathways associated with stimulating autophagy in adipocytes

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2015.3

1 reference

5 September 2017

1 reference

PubMed ID

26794269